Literature DB >> 27042538

Natural Micronized Progesterone Sustained Release (SR) and Luteal Phase: Role Redefined!!

Sonia Malik1, Korukonda Krishnaprasad2.   

Abstract

Role of progesterone in reproductive medicine is evolving with its suggested clinical role for the hormonal and nonhormonal actions in reproductive medicine. The main function of progesterone is to induce 'secretory' changes in endometrium that is further complimented by its immunomodulatory and anti-inflammatory actions. It positively modulates PIBF, NK cells and HOXA 10 genes for better implantation. MHRA recommends Serum Progesterone levels ≥14ng/ml in the mid-luteal phase for supporting pregnancy adequately. Oral Natural Micronized Progesterone SR formulation represents a therapeutic advance in this direction offering 'therapeutic compliance' with oral formulation while avoiding the local side effects related to long-term patient compliance in reproductive disorders. The formulation offers round the clock efficiency and efficacy with single dose administration thereby improving patient convenience and compliance. This formulation has been marketed globally since 1986 utilizing the well validated drug delivery system involving Methylcellulose base. The clinical utility of this formulation is further suggested especially in various conditions related with luteal phase insufficiency and Bad obstetric history (BOH) or luteal phase support in ART. The level of evidence has been quite robust with several clinical studies including Prescription Event Monitoring and Investigator initiated studies supporting the clinical role of oral NMP SR formulation especially in 'Real world' clinic settings for Luteal phase insufficiency that may be physiological or iatrogenic.

Entities:  

Keywords:  Bad obstetric history; Luteal phase support; Prescription event monitoring

Year:  2016        PMID: 27042538      PMCID: PMC4800604          DOI: 10.7860/JCDR/2016/17278.7212

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  23 in total

Review 1.  Using progestins in clinical practice.

Authors:  B S Apgar; G Greenberg
Journal:  Am Fam Physician       Date:  2000-10-15       Impact factor: 3.292

2.  A randomized trial of micronized progesterone for the prevention of recurrent preterm birth.

Authors:  Melanie M Glover; David S McKenna; Cathy M Downing; Dana B Smith; Christopher S Croom; Jiri D Sonek
Journal:  Am J Perinatol       Date:  2011-03-04       Impact factor: 1.862

3.  Progestogen administration in pregnancy may prevent preterm delivery.

Authors:  M J Keirse
Journal:  Br J Obstet Gynaecol       Date:  1990-02

4.  Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor.

Authors:  Manju Choudhary; Amita Suneja; Neelam B Vaid; Kiran Guleria; M M A Faridi
Journal:  Int J Gynaecol Obstet       Date:  2014-04-03       Impact factor: 3.561

5.  Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study.

Authors:  Baidya Nath Chakravarty; Hasibul Hasan Shirazee; Purvita Dam; Sourendra Kanta Goswami; Ratna Chatterjee; Sanghamitra Ghosh
Journal:  J Steroid Biochem Mol Biol       Date:  2005-10-05       Impact factor: 4.292

6.  Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone.

Authors:  J L Pouly; S Bassil; R Frydman; B Hedon; B Nicollet; Y Prada; J M Antoine; R Zambrano; J Donnez
Journal:  Hum Reprod       Date:  1996-10       Impact factor: 6.918

7.  Efficacy of oral micronized progesterone in the treatment of luteal phase defects.

Authors:  G N Frishman; S C Klock; A A Luciano; J C Nulsen
Journal:  J Reprod Med       Date:  1995-07       Impact factor: 0.142

8.  Pregnancies following ovum donation in gonadal dysgenesis.

Authors:  D Cornet; S Alvarez; J M Antoine; C Tibi; J Mandelbaum; M Plachot; J Salat-Baroux
Journal:  Hum Reprod       Date:  1990-04       Impact factor: 6.918

9.  Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study.

Authors:  Sanghamitra Ghosh; Ratna Chattopadhyay; Sourendrakanta Goswami; Koel Chaudhury; Baidyanath Chakravarty; Ashalatha Ganesh
Journal:  J Obstet Gynaecol Res       Date:  2014-07       Impact factor: 1.730

Review 10.  Progestagen therapy for recurrent miscarriage.

Authors:  Julia Szekeres-Bartho; Juan Balasch
Journal:  Hum Reprod Update       Date:  2007-11-22       Impact factor: 15.610

View more
  2 in total

Review 1.  Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse.

Authors:  Lingling Salang; Danielle M Teixeira; Ivan Solà; Jen Sothornwit; Wellington P Martins; Magdalena Bofill Rodriguez; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2022-08-24

Review 2.  A review of conventional and sustained-release formulations of oral natural micronized progesterone in obstetric indications.

Authors:  Girija Narendrakumar Wagh; K M Kundavi Shankar; Sumitra Bachani
Journal:  Drugs Context       Date:  2021-10-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.